Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Research & Development (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Research & Development for 7 consecutive years, with $83.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 16.73% to $83.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $316.6 million, a 31.77% increase, with the full-year FY2025 number at $316.6 million, up 31.77% from a year prior.
  • Research & Development was $83.8 million for Q4 2025 at Kymera Therapeutics, up from $74.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $83.8 million in Q4 2025 to a low of $26.0 million in Q1 2021.
  • A 5-year average of $52.4 million and a median of $46.9 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 154.87% in 2021, then grew 9.66% in 2023.
  • Kymera Therapeutics' Research & Development stood at $37.5 million in 2021, then grew by 14.93% to $43.1 million in 2022, then grew by 22.81% to $53.0 million in 2023, then skyrocketed by 35.58% to $71.8 million in 2024, then increased by 16.73% to $83.8 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Research & Development are $83.8 million (Q4 2025), $74.1 million (Q3 2025), and $78.4 million (Q2 2025).